Vote Scores

Home / Companies / Lipocine Inc. / 3 Jun 2026

Meeting · year to 30 June 202629 filers reporting

Lipocine Inc.: meeting of 3 Jun 2026

Votes reported on Form N-PX, item by item

29 Form N-PX filers reported votes at the Lipocine Inc. meeting of 3 Jun 2026. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

4 nominees; 45.0% of reported votes for; 4 filers withheld from or voted against at least one nominee.

72 vote records from 5 filers. 2 of the 5 filers that marked the item either way voted against management.

60.0% for0.0% against40.0% other40.0% against management5 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

55 vote records from 28 filers. 0 of the 25 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

85.7% for0.0% against14.3% other0.0% against management28 filers94.8% for0.0% against5.2% other0.0% against management1,210,795 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

18 vote records from 5 filers. 0 of the 5 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management5 filers100.0% for0.0% against0.0% against management219,232 reported shares
4

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

21 vote records from 6 filers. 0 of the 6 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management6 filers100.0% for0.0% against0.0% against management220,111 reported shares, counted once per item in this group
5

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

18 vote records from 5 filers. 3 of the 5 filers that marked the item either way voted against management.

40.0% for60.0% against60.0% against management5 filers70.0% for30.0% against30.0% against management219,232 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesNo reportForNo report
FidelityForForFor
DimensionalAbstain or withhold *ForFor
State Street and SPDRNo reportForNo report
Charles SchwabForForFor
Northern Trust and FlexSharesNo reportForNo report
T. Rowe PriceNo reportForNo report
BNY MellonNo reportForNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Lipocine Inc. meeting?

29 Form N-PX filers reported votes at the meeting of 3 Jun 2026. On say-on-pay, 0 of 25 voted against management (0.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Lipocine Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Lipocine Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Lipocine Inc. with a meeting date within three days of 3 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.